Brief: Maplight Announces Topline Results From Phase 2 Iris Study For Ml-004 In Autism Spectrum Disorder
22/06/2026 12:44
BRIEF-Maplight Announces Topline Results From Phase 2 Iris Study For Ml-004 In Autism Spectrum Disorder June 22 (Reuters) - Maplight Therapeutics Inc MPLT.O:
MAPLIGHT ANNOUNCES TOPLINE RESULTS FROM PHASE 2 IRIS STUDY FOR ML-004 IN AUTISM SPECTRUM DISORDER
MAPLIGHT THERAPEUTICS - PHASE 2 IRIS TRIAL DOES NOT MEET PRIMARY ENDPOINT IN ASD
MAPLIGHT THERAPEUTICS - ML-004 GENERALLY WELL-TOLERATED WITH NO SEVERE OR SERIOUS ADVERSE EVENTS IN PHASE 2 IRIS TRIAL
MAPLIGHT THERAPEUTICS - TO ENGAGE WITH FDA IN END-OF-PHASE 2 MEETING FOR ML-004
Source text: ID:nGNXb7GH5X
Further company coverage: MPLT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MapLight Therapeutics
See all newsUS and German scientists win Nobel medicine prize for work on light and brain (updated)
U.S. RESEARCH ROUNDUP- BioLife Solutions, Gossamer Bio, Intuit
MapLight's schizophrenia drug fails once-daily test, shares plunge
U.S. RESEARCH ROUNDUP-Deckers Brands, Rollins, United Rentals
U.S. STOCKS ON THE MOVE-Abbvie, AMC, Getty